DAFNA CAPITAL MANAGEMENT, LLC

Adviser information for DAFNA CAPITAL MANAGEMENT, LLC last updated from Form ADV on March 27th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.

Advisory Business

Type of Organization Limited Liability Company
Fiscal Year End DECEMBER
Legal Location Delaware, United States

Employees

Total Number of Employees 8
Investment Advisory/Research 7
Registered Broker-Dealer Representatives 0
Registered State Investment Advisers 0
Licensed Agents of an Insurance Company 0
No. of Firms/People that Solicit Clients 0

RAUM

Provides Management of Securities Portfolios Yes
Type Accounts RAUM
Discretionary 4 $647.9M
Non-Discretionary 0 $0
Total 4 $647.9M

Clients

Type Number RAUM
Individuals 0 $0
HNW Individuals 0 $0
Banking or thrift institutions 0 $0
Investment companies 0 $0
Business development companies 0 $0
Pooled investment vehicles 4 $647.9M
Pension and profit sharing plans 0 $0
Charitable organizations 0 $0
State or municipal gov entities 0 $0
Other investment advisers 0 $0
Insurance companies 0 $0
Sovereign wealth funds and foreign official institutions 0 $0
Corporations or other businesses 0 $0
Other 0 $0
Type Number
No. of Non-RAUM Clients 0
No. of Non-U.S. Clients 25

Services

Advisory Services Portfolio management for pooled investment vehicles
Compensation % of AUMPerformance-based fees

Identifiers

SEC RIA File Number 801-62559
SEC ERA File Number 801-62559
SEC CIK Numbers 1389933
SEC CRD Numbers 129053
Legal Entity Identifier 254900W3EEPXDZYS3V12

Principal Office

10990 WILSHIRE BOULEVARD
SUITE 1400
LOS ANGELES
CA
United States
Monday - Friday, 5:30 AM TO 4:00 PM
Tel: 310-954-3200, Fax: 310-445-6594

Chief Compliance Officer

XUN LIN
DIRECTOR OF FINANCE
10990 WILSHIRE BOULEVARD
SUITE 1400
LOS ANGELES
CA
United States
Tel: 310-954-3200
Fax: 310-445-6594
(Full email address available in API data)

Regulatory Contact

NATHAN FISCHEL
CEO
10990 WILSHIRE BOULEVARD
SUITE 1400
LOS ANGELES
CA
United States
Tel: 310-954-3200
Fax: 310-445-6594
(Full email address available in API data)

Industry Affiliates

None

Private Funds

Name Type Assets $USD Min Investment $USD No. Owners
DAFNA FUND, L.P. SERIES A Hedge Fund $261.9M $1.0M 77
DAFNA FUND, L.P. SERIES C Hedge Fund $142.0M $1.0M 21
DAFNA INTERNATIONAL FUND LTD. CLASS A Hedge Fund $203.1M $1.0M 45
DAFNA INTERNATIONAL FUND LTD. CLASS C Hedge Fund $36.7M $1.0M 11
DAFNA LIFESCIENCE SELECT, L.P. Hedge Fund $179.0M $1.0M 3
DAFNA LIFESCIENCE, L.P. Hedge Fund $468.9M $1.0M 3

Control Persons

Name Type Entity Title Since Ownership
FISCHEL, NATHAN Individual CHIEF EXECUTIVE OFFICER 02/2000 < 5%
GHODSIAN, FARIBA, FISCHEL Individual CHIEF INVESTMENT OFFICER 11/2002 < 5%
FISCHEL, NATHAN Individual THE FISCHEL-GHODSIAN FAMILY TRUST TRUSTEE 04/1999 > 75%
GHODSIAN, FARIBA, FISCHEL Individual THE FISCHEL-GHODSIAN FAMILY TRUST TRUSTEE 04/1999 > 75%
DAFNA HOLDINGS, L.P. Domestic Entity MEMBER 01/2013 > 75%
THE FISCHEL-GHODSIAN FAMILY TRUST Domestic Entity DAFNA HOLDINGS, L.P. LIMITED PARTNER 01/2013 > 75%
DAFNA HOLDINGS CORP. Domestic Entity DAFNA HOLDINGS, L.P. GENERAL PARTNER 01/2013
LIN, XUN Individual CHIEF COMPLIANCE OFFICER 11/2017 < 5%
DLF1 TRUST Domestic Entity DAFNA HOLDINGS, L.P. LIMITED PARTNER 06/2021 25-50%
DCF2 TRUST Domestic Entity DAFNA HOLDINGS, L.P. LIMITED PARTNER 06/2021 25-50%
DSF3 TRUST Domestic Entity DAFNA HOLDINGS, L.P. LIMITED PARTNER 06/2021 25-50%
GHODSIAN, FARIBA, FISCHEL Individual DLF1 TRUST TRUSTEE 05/2021 25-50%
GHODSIAN, FARIBA, FISCHEL Individual DCF2 TRUST TRUSTEE 05/2021 25-50%
GHODSIAN, FARIBA, FISCHEL Individual DSF3 TRUST TRUSTEE 05/2021 25-50%

No. Employees, Historic

10502020202120222023202420258 on 3/30/20207 on 3/30/20217 on 3/30/20227 on 11/2/20227 on 3/30/20238 on 3/27/2024

RAUM, Historic

800M400M0202020212022202320242025529288591 on 3/30/2020741970101 on 3/30/2021589457792 on 3/30/2022589457792 on 11/2/2022542728476 on 3/30/2023647896107 on 3/27/2024

No. Clients, Historic

10502020202120222023202420254 on 3/30/20204 on 3/30/20214 on 3/30/20224 on 11/2/20224 on 3/30/20234 on 3/27/2024

Holdings

From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name Class Value $USD # Shares Private Fund
2SEVENTY BIO INC COMMON STOCK 4M 1M
ACCURAY INC COM 2M 1M
ACELYRIN INC COM 3M 694K
ACRIVON THERAPEUTICS INC COMMON STOCK 704K 121K
ADAPTIMMUNE THERAPEUTICS PLC SPONDS ADR 333K 341K
ADC THERAPEUTICS SA SHS 645K 204K
ADICET BIO INC COM 726K 600K
ALECTOR INC COM 4M 913K
ALKERMES PLC SHS 3M 121K
ALLOGENE THERAPEUTICS INC COM 1M 605K
ALTO NEUROSCIENCE INC COM SHS 1M 120K
APREA THERAPEUTICS INC COM NEW 558K 137K
AQUESTIVE THERAPEUTICS INC COM 1M 530K
ARCUS BIOSCIENCES INC COM 4M 253K
ARS PHARMACEUTICALS INC COM 2M 239K
ASCENDIS PHARMA A/S NOTE 2.250% 4/0 4M
ASCENDIS PHARMA A/S SPONSORED ADR 11M 81K
ASTRIA THERAPEUTICS INC COM 2M 274K
ATRICURE INC COM 15M 639K
AUTOLUS THERAPEUTICS PLC SPON ADS 1M 347K
AXOGEN INC COM 7M 936K
BICYCLE THERAPEUTICS PLC SPONSORED ADS 2M 122K
BIOCRYST PHARMACEUTICALS INC COM 4M 705K
BIOHAVEN LTD COM 8M 219K
BLUEPRINT MEDICINES CORP COM 11M 105K
BRAINSWAY LTD SPONSORED ADS 2M 298K
CENTESSA PHARMACEUTICALS PLC SPONSORED ADS 1M 123K
CENTURY THERAPEUTICS INC COM 4M 2M
COMPASS PATHWAYS PLC SPONSORED ADS 1M 243K
COMPASS THERAPEUTICS INC COM 117K 117K
COMPUGEN LTD ORD 776K 462K
CYTOKINETICS INC COM NEW 22M 398K
DAY ONE BIOPHARMACEUTICALS I COM 9M 666K
DEXCOM INC COM 7M 66K
EDGEWISE THERAPEUTICS INC COM 5M 290K
FOGHORN THERAPEUTICS INC COM 241K 42K
GALAPAGOS NV SPON ADR 3M 130K
GOSSAMER BIO INC COM 1M 1M
IDEAYA BIOSCIENCES INC COM 15M 422K
IMMATICS NV SHS 2M 145K
IMMUNOVANT INC COM 1M 48K
INOGEN INC COM 2M 209K
INSULET CORP COM 3M 16K
ISHARES NASDAQ BIOTECH INDX ETF 14M 103K
ITEOS THERAPEUTICS INC COM 2M 144K
KALVISTA PHARMACEUTICALS INC COM 10M 807K
KARYOPHARM THERAPEUTICS INC COM 167K 193K
KEROS THERAPEUTICS INC COM 3M 68K
KURA ONCOLOGY INC COM 9M 424K
LARIMAR THERAPEUTICS INC COM 5M 640K
LINEAGE CELL THERAPEUTICS IN COM 1M 1M
MASIMO CORP COM 378K 3K
MEDIWOUND LTD SHS NEW 2M 124K
MERUS N V COM 24M 409K
MINERALYS THERAPEUTICS INC COM 1M 119K
MORPHIC HOLDING INC COM 8M 232K
NEUROCRINE BIOSCIENCES INC COM 10M 72K
NEUROGENE INC COM 400K 11K
NEURONETICS INC COM 565K 314K
NEVRO CORP COM 236K 28K
NYXOAH S A SHS 754K 108K
ORIC PHARMACEUTICALS INC COM 255K 36K
PERSPECTIVE THERAPEUTICS INC COM NEW 2M 232K
POLYPID LTD COM 795K 185K
PROCEPT BIOROBOTICS CORP COM 855K 14K
PROQR THERAPEUTICS N V SHS EURO 2M 906K
REGULUS THERAPEUTICS INC COM 2M 895K
REVOLUTION MEDICINES INC COM 20M 512K
SAGE THERAPEUTICS INC COM 1M 116K
SPDR S&P BIOTECH ETF ETF 41M 445K
SPERO THERAPEUTICS INC COM 163K 125K
STEREOTAXIS INC COM NEW 25M 14M
STOKE THERAPEUTICS INC COM 3M 207K
STRUCTURE THERAPEUTICS INC SPONSORED ADS 196K 5K
SUTRO BIOPHARMA INC COM 966K 330K
SYNDAX PHARMACEUTICALS INC COM 13M 657K
SYROS PHARMACEUTICALS INC COM NEW 701K 136K
TANDEM DIABETES CARE INC COM NEW 8M 204K
TERNS PHARMACEUTICALS INC COM 586K 86K
TOURMALINE BIO INC COM 977K 76K
UROGEN PHARMA LTD COM 8M 469K
VIKING THERAPEUTICS INC COM 10M 189K
XENON PHARMACEUTICALS INC COM 11M 274K